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Intestinal microfold (M) cells are epithelial cells primarily present on Peyer's patches (PPs) in the small
intestine. The ability of M cells to shuttle antigens into the PP for appropriate immune responses makes
M cells a target for next-generation oral vaccine delivery. In this regard, discovery of M cell-speciﬁc
receptors are of great interest, which could act as molecular tags for targeted delivery of cargo to M cells.
Here, using a monoclonal antibody we generated to the Sialic acid-binding immunoglobulin-like lectin F
(Siglec-F), we show that Siglec-F is expressed on mouse M cells in the small intestine. Immunohisto-
chemical analysis of the PP tissue sections shows that Siglec-F is expressed on the surface of the M cell
membrane exposed to the intestinal lumen. Anti-Siglec-F antibody injected into the mouse small in-
testine bound to M cells, demonstrating the potential to target M cells via Siglec-F.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Intestinal microfold (M) cells are small intestinal epithelial cells
localized on the Peyer's patches (PPs) [1]. M cells actively transport
luminal antigens from foods, viruses, and bacteria into the PPs,
leading to induction of the appropriate immune response [2].
Because of the role of M cells in antigen transport, targeted delivery
of antigens to M cells has been recognized as an approach to
enhance oral vaccine efﬁcacy [3]. Towards this end, several well-
deﬁned cell surface markers on M cells have been investigated as
targets to deliver antigens to M cells. Targets investigated to date
include a1-2 fucosylated glycans expressed on murine M cells that
are recognized by the monoclonal antibody NKM16-2-4 [4], and
glycoprotein 2 (GP2), an M cell speciﬁc protein that can be targeted
with an anti-GP2 [5,6]. Oral administration of antigen conjugated to
either the NKM16-2-4 or anti-GP2 antibody, greatly elevated serumer's patch; Siglec, sialic acid-
paeus agglutinin-I.
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M cell-targeted oral vaccine [4,5].
Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a
family of proteins that recognize sialic acid residues on glycopro-
teins and glycolipids [7]. Siglecs were ﬁrst characterized as immune
cell receptors with functions including: regulation of cellular acti-
vation, tolerance induction, and pathogen recognition and uptake
[7]. Recent studies, however, have revealed that several Siglecs are
also expressed on non-immune cells, suggesting that Siglecs play
roles beyond modulating immune cell responses. For example,
Siglec-4 is well known to be expressed primarily on oligodendro-
cytes of the central nervous system [7], Siglec-6 in the placenta [8],
Siglec-12 in the prostate and kidney [9], Siglec-5/14 on amniotic
epithelium [10], and Siglec-5 on human M cells [11]. Due to their
restricted expression pattern and efﬁcient endocytic properties,
Siglecs remain promising targets for delivering therapeutics to
speciﬁc immune and non-immune cell types alike [12].
Siglec-F is a member of the Siglec family and was ﬁrst identiﬁed
as an eosinophil marker in mouse [7]. Siglec-F recognizes the
NeuAca2-3Gal[6S]b1-4GlcNAc motif printed on a synthetic glycan
microarray [13], and it is proposed that binding of Siglec-F to a
related glycan expressed on mouse lung potentiates eosinophil
death in the lung during allergic asthma [14]. Accordingly, Siglec-F
deﬁcient mice exhibit increased numbers of lung-inﬁltrating eo-
sinophils during an asthmatic state [15]. While these studies haveunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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role of Siglec-F in other cell-types, such as alveolar macrophages
[16] and activated T cells [15], remains unclear.
We generated a monoclonal antibody recognizing Siglec-F to
investigate its cell type expression and biological roles in mouse
tissues and cells. Although attention to expression of Siglec-F has
focused on immune cells in blood, spleen, and lymph nodes, we
noted a single report of the presence of Siglec-F mRNA in mouse M
cells [17]. As described here, we found that Siglec-F protein is
indeed expressed on the luminal surface of small intestinal M cells.
Furthermore, our Siglec-F antibody bound to M cells upon injection
into the small intestine, demonstrating the potential of M cell tar-
geting via Siglec-F.
2. Materials and methods
2.1. Animals
C57BL/6J WT and Siglec-F KO (Mutant Mouse Resource Research
Center, University of California Davis, USA) mice and Lewis rats
were maintained in the speciﬁc pathogen free animal facility at The
Scripps Research Institute (La Jolla, USA). C57BL/6J and Balb/c mice
were maintained in the speciﬁc pathogen free animal facility at the
University of East Anglia (Norwich, UK). Animal use in this study
was in the accordance with the guidelines of the Institutional An-
imal Care and Use Committee of The Scripps Research Institute and
the UK Home Ofﬁce.
2.2. Anti-Siglec-F monoclonal antibody generation
The anti-Siglec-F monoclonal antibody (rat IgG2b, clone 9C7)
was generated as described previously [18]. Brieﬂy, Lewis rats were
immunized with Siglec-F-expressing CHO cells emulsiﬁed in
complete Freund's adjuvant (Difco Laboratories). Following two
boosts of the cells emulsiﬁed in incomplete Freund's adjuvant
(Difco Laboratories), the immunized rats were sacriﬁced and the
common iliac lymph nodes were harvested to generate hybrid-
omas. The established hybridomas were screened for reactivity to
Siglec-F-CHO cells and Siglec-F-expressing HEK293 cells by ﬂow
cytometry. The selected anti-Siglec-F expressing hybridoma was
grown for 7e10 days, and the antibody was puriﬁed from the cul-
ture supernatant and labelled with Alexa Fluor-647 (Life
Technologies).
2.3. Flow cytometry
PPs were harvested from mouse small intestine and vortexed in
PBS vigorously. The supernatant was removed, and this washing
step was repeated three times. Washed PPs were incubated with
10 ml of PBS containing 5 mM EDTA and 1 mM DTT for 30 min at
37 C, in order to remove cells localized in the epithelia. The solu-
tion was passed through a 40 mm-cell strainer and centrifuged. The
harvested cells were incubated with FcR-blocking antibody (Bio-
legend, clone 93) and stainedwith anti-M cell antibody NKM16-2-4
(MP Biomedicals) for 30 min at 4 C, followed by Biotin-labelled
anti-rat IgG2c (Southern Biotech). The cells were further stained
with a cocktail of Alexa647-labelled anti-Siglec-F antibody,
Alexa700-labelled anti-mouse CD45 (Biolegend, clone: 30-F11), PE-
labelled anti-mouse CCR3 (Biolegend, J073E5), PE-Cy7-labelled
CD11b (Biolegend, M1/70), FITC-labelled UEA-I (Vector lab), and
Paciﬁc blue-labelled streptavidin (Life Technologies). The stained
cells were washed and resuspended in 0.3 mg/ml propidium iodide
for dead cell exclusion prior to analysis on Fortessa or LSR II cellanalyzers (BD Biosciences). Data were analyzed by FlowJo
(Treestar).
2.4. Microscopy
Terminal ileum PPs were harvested from C57BL/6J mice, washed
in 1x PBS, snap frozen in OCT (Bright CRYO-M-BED), and cryosec-
tioned at 8-mm thickness. Sections were ﬁxed for 5minwith20 C
methanol, washed once with PBS containing 0.05% Tween-20 (PBS-
T), and washed twice with PBS. All subsequent incubations were
performed at RT. Sections were treated with 3% H2O2 in PBS for
30 min. After washing once with PBS-T and twice with PBS, slides
were blocked with PBS containing 6% BSA and 10% normal mouse
serum (Southern Biotech) for 30 min. Anti-mouse Siglec-F or iso-
type control (10 mg/ml) and UEA-I-FITC (20 mg/ml) were applied for
60 min. After washing, as described above, sections were incubated
for 30 minwith mouse anti-rat IgG2b-HRP (Southern Biotech, 2 mg/
ml). Sections were washed once with PBS-T, washed four times
with 1x PBS, and treated for 5 min with Cy-3 Plus TSA reagent
(Perkin Elmer) according to the manufacturer's instructions. After
washing once with PBS-T and four times with PBS, sections were
incubated with anti-mouse M cell antibody NKM16-2-4 (25 mg/ml).
After 60 min the slides were washed and treated with biotinylated
anti-rat IgG2c (10 mg/ml) for 30 min, washed, and stained for
20 min with Alexa647 conjugated streptavidin and counterstained
with DAPI (5 mg/ml). Sections were imaged with the Zeiss Axio
Imager M2, and data were analyzed with ZEN 2 (blue edition).
2.5. Intestinal loop assay
Balb/c mice were anesthetized with a continuous ﬂow of iso-
ﬂurane. The small intestine was exposed via laparotomy, and an
intestinal loop containing PPs was made using threads (Fig. 3A).
Five micrograms of Alexa647-labelled anti-Siglec-F or isotype
control antibody (Rat IgG2b, Biolegend) was injected into the loop.
The mice were sacriﬁced 15 min after inoculation, and PPs were
harvested. The Alexa647 signal associated with M cells was
analyzed by ﬂow cytometry.
3. Results and discussion
3.1. Generation of a Siglec-F monoclonal antibody
In order to study Siglec-F expression proﬁle on mouse tissues,
we generated a monoclonal antibody to Siglec-F. Brieﬂy, Lewis rats
were immunized with Siglec-F expressing CHO cells. Hybridomas
were established by fusing myeloma cell line with the lymphocytes
from common iliac lymph nodes of the immunized animals. Hy-
bridoma screening was performed based on the antibody reactivity
to Siglec-F expressing CHO cells and HEK293 cells by ﬂow cytom-
etry. The established clone 9C7 produced a rat IgG2b monoclonal
antibody, which binds to Siglec-F expressed on HEK293 cells
(Fig. 1).
3.2. Expression of Siglec-F on PP M cells
A report showing Siglec-F mRNA expression in mouse M cells
[17] motivated us to investigate Siglec-F protein expression on
mouse M cells using our Siglec-F monoclonal antibody (clone 9C7).
PP M cells were identiﬁed as CD45UEA-IþNKM16-2-4þ by ﬂow
cytometric analysis, as reported previously [17]. We found that PP
M cells did indeed express Siglec-F when compared to an isotype
control at levels comparable to eosinophils (CD45þCD11bþCCR3þ)
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Fig. 1. A new anti-Siglec-F monoclonal antibody binds to Siglec-F expressing
HEK293 cells. HEK 293 cells expressing Siglec-F or mock transfectant were stained
with Alexa 647-labelled Siglec-F (Black) or isotype control (Grey) antibody. The stained
cells were analyzed by ﬂow cytometry. Data are representative of two independent
experiments with similar results.
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speciﬁc for Siglec-F, since M cells isolated from Siglec-F KO mice
stained at levels equivalent to the isotype control (Fig. 2B). In the
immunohistochemical analysis, we found that Siglec-F stainingwas
co-localized with the UEA-I and NKM16-2-4 signals in frozen sec-
tions of PP (Fig. 2C). Of note, Siglec-F expression was observed on
the intestinal luminal surface of M cells (Fig 2C, arrows). Together
these data demonstrate that Siglec-F is expressed on the luminal
surface of mouse PP M cells.3.3. In vivo M cell targeting by anti-Siglec-F antibody
To test whether M cells are targeted by Siglec-F antibody,Fig. 2. Siglec-F expression on PP M cells. (A) Cells isolated from the epithelial fraction of P
with the other cell surface markers. Stained cells were analyzed by ﬂow cytometry. Dead ce
Siglec-F KO mice were analyzed for their reactivity to the Siglec-F antibody clone 9C7 as in
eosinophils. ***, p < 0.001 and N.S., not statistically signiﬁcant in the Student's t-test (n ¼ 4).
2-4. Blue signals show nuclear staining with DAPI. The bottom panels are enlarged images o
signals. White bars in the top and bottom panel are 50 mm and 10 mm, respectively. Data aAlexa647-labelled anti-Siglec-F or an isotype control antibody were
injected intraluminally into a small intestine loop created by liga-
tures (Fig. 3A). PPs were harvested, and cells were analyzed by ﬂow
cytometry. We found that the Siglec-F antibody bound to M cells,
but not to eosinophils - presumably because the eosinophils are not
exposed to the intestinal lumen - demonstrating the potential of M
cell targeting through Siglec-F via the intestinal lumen (Fig. 3B).
Our ﬁndings suggest a novel role for Siglec-F in M cells, opening
up several key questions to be addressed; a) Since Siglec-F is well
documented to have endocytic activity [19], to what extent might it
contribute to the antigen transport by M cells? In this regard,
Siglec-F has been shown to internalize the sialylated microbe
Neisseria meningitides into the cell [19], suggesting a potential role
for Siglec-F onM cells as a receptor for sialylatedmicroorganisms in
the gut. b) Is Siglec-F involved in survival of M cells? To determine
whether the function of Siglec-F on M cells is analogous to its
function in eosinophils, it will be important to test whether anti-
bodies and glycan ligands toward Siglec-F also regulate the survival
of M cells.
In humans, Siglec-8 is characterized as a functional paralogue of
Siglec-F, exhibiting the same expression pattern and glycan-
binding speciﬁcity [7]. Interestingly, Siglec-5 has been reported to
be expressed in human M cells [11]. Therefore, it would be of in-
terest to assess whether Siglec-5 and Siglec-F are functional
paralogues on M cells.
In summary, we have identiﬁed Siglec-F expression onmouse M
cells. The receptor can be targeted by antibody in vivo, which sug-
gests that Siglec-F could potentially be exploited to deliver antigen
to M cells. The discovery of Siglec receptors on both mouse (Siglec-
F) and human (Siglec-5) M cells suggests a potentially conserved
biological function for Siglecs in the gut.Ps were stained with anti-Siglec-F (Black) or isotype control (Grey) antibody together
lls were excluded from the analysis by propidium iodide staining. (B) PPs from WT and
(A). Mean ﬂuorescent intensity (MFI) in Siglec-F staining is shown for both M cells and
(C) Frozen sections of PPs were stained with anti-Siglec-F antibody, UEA-I, and NKM16-
f the luminal side of PPs (white box). White arrows show the overlapping of the three
re representative of at least two independent experiments with similar results.
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Fig. 3. In vivo M cell targeting by anti-Siglec-F antibody. Alexa647-labelled anti-
Siglec-F (Black) or isotype control (Grey) antibody was injected into the small intes-
tine of Balb/c mice. After 15 min of inoculation, PPs were harvested, and the cells were
stained as in Fig. 2. Data are representative of two independent experiments with
similar results.
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